These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Issues in clinical trials of prophylaxis of fungal infections. Powers JH Clin Infect Dis; 2004 Oct; 39 Suppl 4():S211-7. PubMed ID: 15546120 [TBL] [Abstract][Full Text] [Related]
3. The design of clinical trials that evaluate antifungal prophylaxis and combination therapy: introduction and overview. Rex JH; Wingard JR; Wenzel R; Herbrecht R; Sobel J; Edwards JE Clin Infect Dis; 2004 Oct; 39 Suppl 4():S165-9. PubMed ID: 15546112 [TBL] [Abstract][Full Text] [Related]
4. Combination therapy for invasive mycoses: evaluation of past clinical trial designs. Sobel JD Clin Infect Dis; 2004 Oct; 39 Suppl 4():S224-7. PubMed ID: 15546122 [TBL] [Abstract][Full Text] [Related]
5. Clinical practice: combination antifungal therapy for mold infections: much ado about nothing? Vazquez JA Clin Infect Dis; 2008 Jun; 46(12):1889-901. PubMed ID: 18466092 [TBL] [Abstract][Full Text] [Related]
6. Design of efficacy trials of cytokines in combination with antifungal drugs. Kullberg BJ; Oude Lashof AM; Netea MG Clin Infect Dis; 2004 Oct; 39 Suppl 4():S218-23. PubMed ID: 15546121 [TBL] [Abstract][Full Text] [Related]
7. Antifungal prophylaxis in solid-organ transplant recipients: considerations for clinical trial design. Singh N Clin Infect Dis; 2004 Oct; 39 Suppl 4():S200-6. PubMed ID: 15546118 [TBL] [Abstract][Full Text] [Related]
8. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
14. Forum report: issues in the design of trials of drugs for the treatment of invasive aspergillosis. Bennett JE; Powers J; de Pauw B; Dismukes W; Galgiani J; Glauser M; Herbrecht R; Kauffman C; Lee J; Pappas P; Rex J; Verweij P; Viscoli C; Walsh T Clin Infect Dis; 2003 Apr; 36(Suppl 3):S113-6. PubMed ID: 12679894 [TBL] [Abstract][Full Text] [Related]
15. Topical antifungal drugs for the treatment of onychomycosis: an overview of current strategies for monotherapy and combination therapy. Baran R; Kaoukhov A J Eur Acad Dermatol Venereol; 2005 Jan; 19(1):21-9. PubMed ID: 15649187 [TBL] [Abstract][Full Text] [Related]
16. The rationale of combination antifungal therapy in severely immunocompromised patients: empiricism versus evidence-based medicine. Chamilos G; Kontoyiannis DP Curr Opin Infect Dis; 2006 Aug; 19(4):380-5. PubMed ID: 16804387 [TBL] [Abstract][Full Text] [Related]
17. Design of clinical trials of empiric antifungal therapy in patients with persistent febrile neutropenia: considerations and critiques. Sobel JD Pharmacotherapy; 2006 Jun; 26(6 Pt 2):47S-54S. PubMed ID: 16716122 [TBL] [Abstract][Full Text] [Related]
18. Combination antifungal therapy: a critical review of the evidence. Ostrosky-Zeichner L Clin Microbiol Infect; 2008 May; 14 Suppl 4():65-70. PubMed ID: 18430131 [TBL] [Abstract][Full Text] [Related]
19. [Clinical trials in dermatology. Evaluation of the tolerability and efficacy of a topical antifungal agent in the treatment of superficial mycoses]. Queille-Roussel C; Dahan C; Duteil L; Schaefer H; Revuz J; De Prost Y; Guillaume JC; Ortonne JP; Czernielewski J Therapie; 1991; 46(3):201-4. PubMed ID: 1792652 [TBL] [Abstract][Full Text] [Related]
20. Treatment of invasive fungal infections in immunocompromised and transplant patients: AmBiLoad trial and other new data. Muñoz P; Guinea J; Narbona MT; Bouza E Int J Antimicrob Agents; 2008 Nov; 32 Suppl 2():S125-31. PubMed ID: 19013336 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]